Using Mesenchymal Stromal Cells in Islet Transplantation
Using Mesenchymal Stromal Cells in Islet Transplantation
复制标题
DOI：
10.1002/sctm.18-0033
复制
发表时间：
2018-08-01
影响因子：
6
通讯作者：
Jones, Peter M.
中科院分区：
文献类型：
--
作者：
Arzouni, Ahmed A.;Vargas-Seymour, Andreia;Jones, Peter M.
胰岛移植具有治愈1型糖尿病的潜力，但目前的临床移植方案是低效的，因为在移植后即刻功能性胰岛的广泛丧失。在啮齿动物模型中的研究已经证明，间充质干细胞（MSC）与胰岛共移植改善了移植物功能存活和移植结果，并且MSC的一些有益作用归因于MSC分泌的生物活性分子。临床胰岛移植几乎完全通过肝门静脉，这不利于胰岛和MSC的共植入，因此目前的注意力集中在使用MSC衍生产品的无细胞混合物在移植前治疗胰岛。这种方法有可能克服与使用MSC作为人类胰岛移植的辅助治疗相关的许多技术和监管障碍。
Islet transplantation has the potential to cure type 1 diabetes, but current clinical transplantation protocols are inefficient because of the extensive loss of functional islets during the immediate post-transplantation period. Studies in rodent models have demonstrated that co-transplanting mesencyhmal stromal cells (MSCs) with islets improves graft functional survival and transplantation outcomes, and some of the beneficial effects of MSCs are attributable to bioactive molecules secreted by MSCs. Clinical islet transplantation is almost exclusively via the hepatic portal vein, which does not facilitate co-engraftment of islets and MSCs, so attention is currently focused on using cell-free cocktails of MSC-derived products to treat islets prior to transplantation. This approach has the potential to overcome many of the technical and regulatory hurdles associated with using MSCs as an adjuvant therapy for human islet transplantation.